Tony G Co-Investment Holdings Provides Corporate Update

Rhea-AI Summary

Tony G Co-Investment Holdings (CSE: TONY) provided updates on its portfolio company AlClin. The company is progressing towards site registration overseas and drug registration for its NAD+ product. AlClin has installed new industrial cGMP-grade 'isolator' and 'in-line filling' machinery, significantly increasing production capacity from 12,000 NAD+ vials monthly to 1,000 per hour.

Additionally, AlClin received a license from SAHPRA (South Africa Health Products Regulatory Authority) under new Complimentary Medicines regulation for manufacturing, importing, and exporting its tablet range. The company reports strong growth with existing clients and increasing interest from new prospects, including e-commerce platforms.

Positive

• Production capacity increase from 12,000 NAD+ vials/month to 1,000/hour
• Obtained SAHPRA license for manufacturing, import, and export
• Strong growth reported with existing clients
• Expanding interest from new clients including e-commerce platforms

Negative

• None.

Toronto, Ontario--(Newsfile Corp. - December 23, 2024) - Tony G Co-Investment Holdings Ltd. (CSE: TONY) (the "Company" or "TGH") would like to provide the following corporate update. Further to its press release of November 16, 2023, an entity in the Company's investment portfolio, Alclin (PTY) Limited ("AlClin") (https://alclin.com/), is set to achieve both a site registration overseas as well as registration as a drug of its NAD+ (nicotinamide adenine dinucleotide, also known as diphosphopyridine nucleotide) product.

New industrial cGMP-grade 'isolator' and 'in-line filling' machinery has been delivered and installed to support increasing global awareness¹ and demand² for NAD+: boosting maximum capacity from 12,000 NAD+ vials a month to 1,000 per hour.

AlClin was also issued with a licence from SAHPRA (South Africa Health Products Regulatory Authority, South Africa's equivalent of the FDA in the USA) - under a new Complimentary Medicines regulation - to manufacture, import and export its established product tablet range which has been exhibiting strong growth with existing clients and interest from new perspective clients including via e-commerce platforms.

TGH will be continuing on its active roadmap ahead for AlClin and its 'longevity theme'.

For more information, please contact:

Ron Akram
Chief Executive Officer
Tel: +44 786 6464 520
Email: contact@tony.holdings

This press release contains "forward-looking statements", within the meaning of the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, the Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation, concerning the business, operations and financial performance and condition of Tony G Co-Investment Holdings Ltd. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate" "plans", "estimates" or "intends" or stating that certain actions, events or results " may", "could", "would", "might" or "will" be taken, occur or be achieved) are not statements of historical fact and may be "forward-looking statements". Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to materially differ from those reflected in the forward-looking statements.

The forward-looking statements and information in this press release include but are not limited to the Company's intention to defend the litigation with the Fund, the Company's liability under the Debenture and the above-mentioned litigation.

Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to materially differ from those reflected in the forward-looking statements. Such forward-looking statements, including but not limited to statements relating to the Loan and the Company's business strategy, involve risks, uncertainties and other factors which may cause the actual results to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among others, that the litigation referred to herein will be resolved in a manner that is unfavourable to the Company (including any judgment, award or settlement of the litigation that results in the Company incurring liability, costs or expenses that, in the aggregate, exceed the share issuance costs of the Conversion Shares), the Company is required to issue shares other than the Conversion Shares or pay any amount to the plaintiff in defending, resolving, or in connection with, such litigation, and other related matters, or other factors set forth in the Company's publicly filed documents under its profiles at www.sedarplus.ca.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statement prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

The forward-looking information contained in this press release represents the expectations of the Company as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward looking information and should not rely upon this information as of any other date. While the Company may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws.

None of the Canadian Securities Exchange or its Regulation Services Provider (as that term is defined in policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

---

¹ https://www.youtube.com/watch?v=hOPdrKOnAr8

² https://www.ft.com/content/68e07256-4b8c-4e12-a96e-8ad646d6a7fb?utm_source=chatgpt.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235005

FAQ

What is the new production capacity for AlClin's NAD+ vials after machinery upgrade?

After installing new cGMP-grade machinery, AlClin's production capacity increased from 12,000 NAD+ vials per month to 1,000 vials per hour.

What regulatory approval did AlClin receive from SAHPRA in December 2023?

AlClin received a license from SAHPRA under new Complimentary Medicines regulation to manufacture, import, and export its tablet range.

How is AlClin expanding its market presence?

AlClin is expanding through strong growth with existing clients and increasing interest from new prospects, including e-commerce platforms, while pursuing overseas site registration and drug registration for its NAD+ product.

What new manufacturing equipment has AlClin installed?

AlClin has installed new industrial cGMP-grade 'isolator' and 'in-line filling' machinery to support increasing global demand for NAD+.